These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26908627)

  • 41. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.
    Bid HK; London CA; Gao J; Zhong H; Hollingsworth RE; Fernandez S; Mo X; Houghton PJ
    Clin Cancer Res; 2013 Jun; 19(11):2984-94. PubMed ID: 23549869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
    da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
    Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism].
    Chen XY; Yan X; Song BY; Sun J; Mu LJ; Li WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1094-1100. PubMed ID: 35981367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS.
    Huang M; Qiu Q; Xiao Y; Zeng S; Zhan M; Shi M; Zou Y; Ye Y; Liang L; Yang X; Xu H
    Sci Rep; 2016 Apr; 6():23770. PubMed ID: 27044328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.
    Fourniols T; Maggio V; Rafael D; Colaco A; Vidal EG; Lopes A; Schwartz S; Martínez-Barriocanal Á; Preat V; Arango D
    Eur J Pharm Biopharm; 2022 Feb; 171():39-49. PubMed ID: 34998911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
    Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
    Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Aird F; Kandela I; Mantis C;
    Elife; 2017 Jan; 6():. PubMed ID: 28100400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.
    Li F; Yang C; Zhang HB; Ma J; Jia J; Tang X; Zeng J; Chong T; Wang X; He D; Guo P
    Cancer Med; 2019 Aug; 8(10):4792-4805. PubMed ID: 31250978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis.
    Hwang B; Shin SS; Song JH; Choi YH; Kim WJ; Moon SK
    J Nutr Biochem; 2019 Dec; 74():108230. PubMed ID: 31683101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
    Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
    Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.